铜死亡与肿瘤发生机制的研究进展

马 睿, 迪 吉*
青海大学附属医院

摘要


铜死亡是一种新的细胞死亡方式，与肿瘤密切相关。国内外研究表明，铜通过与相关蛋白结合诱导细胞死亡，在不同肿瘤中机制各异。如在胰腺癌中与转运蛋白及基因表达有关；在乳腺癌中与不良预后相关；在结直肠癌中可通过影响铜稳态治疗等。铜死亡相关基因可作为多种肿瘤预后预测因子，但具体机制及通路未知。后续应寻找相关分子靶点和代谢信号通路，探索与其他治疗手段的协同作用。本文综述了铜死亡与肿瘤发生机制的研究进展。

关键词


恶性肿瘤；铜死亡；机制研究；肿瘤微环境

全文:

PDF


参考


[1]Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 74(3), 229-263. https://doi.org/10.3322/caac.21834

[2]Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., Li, L., Wei, W., & He, J. (2024). Cancer incidence and mortality in China, 2022. Journal of the National Cancer Center, 4(1), 47-53. https://doi.org/10.1016/j.jncc.2024.01.006

[3]Yadav, P., Dua, C., & Bajaj, A. (2022). Advances in Engineered Biomaterials Targeting Angiogenesis and Cell Proliferation for Cancer Therapy. Chemical record (New York, N.Y.), 22(12), e202200152. https://doi.org/10.1002/tcr.202200152

[4]Wang, J., Qin, D., Tao, Z., Wang, B., Xie, Y., Wang, Y., Li, B., Cao, J., Qiao, X., Zhong, S., & Hu, X. (2022). Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Frontiers in immunology, 13, 1056932. https://doi.org/10.3389/fimmu.2022.1056932

[5]Zhang, L.X., et al., The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis. Mol Cancer, 2022. 21(1): p. 110.

[6]Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022,375(6586):1254-1261. DOI:10.1126/science.abf0529.

[7]Song GQ, Dong HS, Ma DH, et al. Tetrahedral framework nucleic acid delivered RNA therapeutics significantly attenuate pancreatic cancer progression via inhibition of CTR1-dependent copper absorption[J]. ACS Appl Mater Interfaces, 2021, 13(39): 46334-46342. DOI: 10.1021/acsami.1c13091.

[8]Du Y, Jiang WK, Hou S, et al. A novel cuproptosis-associated gene signature to predict prognosis in patients with pancreatic cancer[J]. Biomed Res Int, 2023, 2023: 3419401. DOI:10.1155/2023/3419401.

[9]Xiao C, Li JY, Hua A, et al. Hyperbaric oxygen boosts antitumor efficacy of copper-diethyldithiocarbamate nanoparticles against pancreatic ductal adenocarcinoma by regulating cancer stem cell metabolism[J]. Research, 2024, 7: 0335. DOI: 10.34133/research.0335.

[10]Huang Y, Gong P, Su L, et al. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma[J]. Sci Rep, 2023, 13(1):20870. DOI: 10.1038/s41598-023-47223-4.

[11]Li L, Li L, Sun Q. High expression of cuproptosis-related SLC31A1 gene in relation to unfavorable outcome and deregulated immune cell infiltration in breast cancer: an analysis based on public databases. BMC Bioinformatics, 2022, 23(1):350.

[12]Guo Q, Qiu P, Pan K, et al. Comprehensive analysis of cuproptosis-related long non-coding RNA signature and personalized therapeutic strategy of breast cancer patients. Front Oncol, 2022, 12:1081089.

[13]KARGINOVA O, WEEKLEY C M, RAOUL A, et al. Inhibition of copper transport induces apoptosis in triple-negative breast cancer cells and suppresses tumor angiogenesis [J]. Mol Cancer Ther, 2019, 18(5): 873-85.

[14]Blockhuys S, Celauro E, Hildesjo C, et al. Defining the human copper proteome and analysis of its expression variation in cancers [J].Metallomics, 2017, 9(2): 112­123.

[15]Li H, Wang J, Wu C, et al. The combination of disulfiram and copper for cancer treatment [J]. Drug Discov Today, 2020, 25(6): 1099­1108.

[16]Guo X, Xu B, Pandey S, et al. Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines [J]. Cancer Lett, 2010, 290(1):104­113.

[17]Baldari S, Di Rocco G, Heffern MC, et al. Effects of copper chelation on BRAF(V600E) positive colon carcinoma cells [J]. Cancers (Basel), 2019, 11(5): 659.

[18]廖全.p53通过调控circFRMD4A抑制肿瘤进展的机制研究[D].南昌大学，2023. DOI：10.27232/d.cnki.gnchu.2023.000051

[19]Gao W, Huang Z, Duan J, et al. Elesclomol induces copperdependent ferroptosis in colorectal cancer cells via degradation of ATP7A [J]. Molecular oncology, 2021, 15(12): 3527-3544.

[20]Lin S, Yang H. Ovarian cancer risk according to circulating zinc and copper concentrations: A meta-analysis and Mendelian randomization study[J]. Clin Nutr, 2021, 40(4): 2464-2468. DOI: 10.1016/j.clnu.2020.10.011.

[21]Yip NC, Fombon IS, Liu P, et al. Disulfiram modulated ROSMAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties[J]. Br J Cancer, 2011, 104(10): 1564-1574. DOI: 10.1038/bjc.2011.126.

[22]Xu B, Wang S, Li R, et al. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2[J]. Cell Death Dis, 2017, 8(5): e2797. DOI: 10.1038/cddis.2017.176.

[23]Gan Y, Liu T, Feng W, et al. Drug repositioning of disulfiram induces endometrioid epithelial ovarian cancer cell death via the both apoptosis and cuproptosis pathways[J]. Oncol Res, 2023, 3

[24]Guo F, Yang Z, Kulbe H, et al. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by disulfiram and copper treatment through ALDH and ROS modulation[J]. Biomed Pharmacother,2019, 118: 109371. DOI: 10.1016/j.biopha.2019.109371.

[25]Fu S, Naing A, Fu C, et al. Overcoming platinum resistance through the use of a copper-lowering agent[J]. Mol Cancer Ther, 2012, 11(6): 1221-1225. DOI: 10.1158/1535-7163.MCT-11-0864.

[26]Kim YJ, Tsang T, Anderson GR, et al. Inhibition of BCL2 family members increases the efficacy of copper chelation in BRAFV600E-Driven melanoma[J]. Cancer Res, 2020, 80(7): 1387-1400. DOI: 10.1158/0008-5472.CAN-19-1784.

[27]LIU J, SHEN H, GU W, et al. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma[J]. Front Immunol,2022, 13(8):960738.

[28]LI G, LUO Q, WANG X, et al. Deep learning reveals cuproptosis features assist in predict prognosis and guide immunotherapy in lung adenocarcinoma[J]. Front Endocrinol (Lausanne), 2022, 13(8):970269.

[29]SUN Z, CHEN X, HUANG X, et al. Cuproptosis and immune-related gene signature predicts immunotherapy response and prognosis in lung adenocarcinoma[J]. Life (Basel), 2023, 13(7):1583.

[30]MA S, ZHU J, WANG M, et al. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma[J]. Transl Lung Cancer Res, 2022, 11(10):2079-2093.

[31]SHEN Y, LI D, LIANG Q, et al. Cross-talk between cuproptosis and ferroptosis regulators defines the tumor microenvironment for the prediction of prognosis and therapies in lung adenocarcinoma[J]. Front Immunol, 2023, 13(1):1029092.

[32]CAI Y, HE Q, LIU W, et al. Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers[J]. Front Oncol, 2022, 12(8):952129.

[33]QIN Y, LIU Y, XIANG X, et al. Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis [J]. Mol Cancer, 2023, 22(1): 59.

[34]CHEN Y, TANG L, HUANG W, et al. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma [J]. Biol Direct, 2023, 18(1): 4.

[35]ZHOU B, GUO L, ZHANG B, et al. Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma [J]. AM J Cancer Res, 2019, 9(11): 2442-55.

[36]CHEN S, LIU P, ZHAO L, et al. A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma [J]. Front Immuno, 2022, 13: 954653.

[37]REN X, LI Y, ZHOU Y, et al. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis [J]. Redox Biol, 2021, 46: 102122.

[38]Polishchuk EV， Merolla A， Lichtmannegger J， et al. Activation of autophagy， observed in liver tissues from patients with wilson disease and from ATP7B-deficient animals， protects hepatocytes from copper-induced apoptosis[J]. Gastroenterology， 2019， 156（4）： 1173-1189.

[39]Liu Y， Huang Y， Zhang J， et al. TIMMDC1 knockdown inhibits growth and metastasis of gastric cancer cells through metabolic inhibition and AKT/GSK3beta/beta-Catenin signaling pathway[J]. Int J Biol Sci， 2018，14（10）： 1256-1267.

[40]Sun, L., Zhang, Y., Yang, B., Sun, S., Zhang, P., Luo, Z., Feng, T., Cui, Z., Zhu, T., Li, Y., Qiu, Z., Fan, G., & Huang, C. (2023). Lactylation of METTL16 promotes cuproptosis via m6A-modification on FDX1 mRNA in gastric cancer. Nature communications, 14(1), 6523. https://doi.org/10.1038/s41467-023-42025-8

[41]Wang, J., Qin, D., Tao, Z., Wang, B., Xie, Y., Wang, Y., Li, B., Cao, J., Qiao, X., Zhong, S., & Hu, X. (2022). Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Frontiers in immunology, 13, 1056932. https://doi.org/10.3389/fimmu.2022.1056932

[42]铜螯合剂有望成为突破乳腺癌、肝癌、肺癌和黑色素瘤等多种癌症耐药瓶颈的治疗药物[J].Cancer Res，2022. DOI：10.1158/0008-5472.CAN-22-0371.

[43]Wang, T., Liu, Y., Li, Q., Luo, Y., Liu, D., & Li, B. (2022). Cuproptosis-related gene FDX1 expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma. Frontiers in immunology, 13, 999823. https://doi.org/10.3389/fimmu.2022.999823

[44]张保朝，丁梦，纪长威，等.基于铜死亡相关基因的肾透明细胞癌中预后模型的构建与应用[J].临床泌尿外科杂志，2023，38（12）：934-941.


Refbacks

  • 当前没有refback。